TrialLung cancer (Amsterdam, Netherlands)2017

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

Dong-Wan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.